
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Efficacy of commercial bacteriophage products against ESKAPE pathogens
Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
Correspondence should be addressed: Nikita S. Kuptsov
Malaya Pirogovskaya, 1a, Moscow, 119435; moc.liamg@snvostpuk
Funding: all study expenses were covered by the funds allocated for the State Assignment on the Development of a personalized approach to the therapy of infections using virulent bacteriophages (Code: Bacteriophage).
Acknowledgements: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, the Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical Biological Agency for their help with bacterial gene sequencing and for subsequent multilocus sequencing typing.
Author contribution: Kuptsov NS — study plan; data acquisition and analysis; manuscript preparation; Kornienko MA — study plan; data analysis; manuscript preparation; Gorodnichev RB, Parfenova TV — data acquisition and analysis; Danilov DI, Malakhova MV — data acquisition; Makarenko GI — sample collection; Shitikov EA — data analysis; manuscript preparation; Ilina EN — manuscript preparation.